While SPP1 absence prevents synaptic loss, it's unclear whether this represents loss of beneficial amyloid clearance or prevention of pathological synapse destruction. This fundamental question affects whether SPP1 should be therapeutically enhanced or inhibited in different disease stages.
Gap type: open_question
Source paper: Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease. (2023, Nat Neurosci, PMID:36747024)
SPP1 signals through CD44 (cell migration) and integrins (inflammatory activation). Pathological synaptic engulfment may require integrin signaling specifically, particularly ITGAX (CD11c). Selective blockade of αXβ2 preserves amyloid clearance while reducing synapse attack. Mechanistically sound but lacks chemical starting point for CNS-penetrant antagonist.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-21 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Therapeutic Hypotheses: SPP1 in Alzheimer's Disease Synaptic Pathology
Title: Early-phase SPP1 enhancement followed by late-phase SPP1 inhibition optimizes amyloid clearance while preventing pathological synapse loss.
Mechanism: SPP1-mediated microglial activation may initially facilitate amyloid phagocytosis. However, sustained SPP1 signaling induces complement-mediated synaptic engulfment. A temporal therapeutic window exists where enhancing SPP1 early (pre-synaptic loss) and inhibiting later (after amyloid burden plateaus
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of SPP1 Therapeutic Hypotheses
Overall Methodological Concerns
Before evaluating individual hypotheses, several cross-cutting issues merit attention:
Fundamental Evidence Gap: The source paper demonstrates that SPP1 absence prevents synaptic loss, but provides no direct evidence that SPP1 enhances amyloid clearance. The beneficial amyloid clearance premise rests on correlation with microglial phagocytic states, not causation. This distinction is fatal to Hypotheses 1 and 3, which depend on preserved amyloid phagocytosis.
Species Translation Risk: 5xFAD mi
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Seven hypotheses survived initial scrutiny at varying credibility levels. Two hypotheses (H1, H6) present fatal or near-fatal conceptual weaknesses—the unproven amyloid clearance premise in H1, and the absent human splice-variant evidence in H6—and are treated as secondary. The remaining five hypotheses are evaluated across druggability, biomarkers and model systems, clinical development constraints, safety, and realistic timeline/cost. A synthesis framework is provided at the end.
Surviving Hypotheses Over
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects SPP1 Signaling from Destructive to Restorative","description":"TREM2 haploinsufficiency shifts SPP1-mediated microglial response from restorative (DAM pathway) to destructive (excessive synapse engulfment). TREM2 agonism converts SPP1 signaling toward neuroprotection. This hypothesis leverages existing TREM2 agonist programs (AL002, HFF3760) by pairing with SPP1 modulation, creating a combination strategy with the highest mechanistic plausibility. Decisive experiment: RNA-seq comparison of SPP1-treated T